Unlocking the Potential of Genomics for Myeloma

The myeloma programme at the SGC is led by Dr Killian Huber

Award Value £200,000

The Structural Genomics Consortium (SGC) catalyses research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of the human genome. The SGC accelerates research in these new areas by making all its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in many universities around the world and in nine global pharmaceutical companies. Together, this network of academic and industry scientists is driving a new scientific and drug discovery ecosystem whose primary aim is to advance science and is less influenced by personal, institutional or commercial gain.

This project will advance our understanding of how myeloma develops and progresses by reversing the established model for drug discovery. It will use chemoproteomics (an approach to discover mechanisms to regulate biological pathways to design new drugs) to identify exactly how existing treatments work. The aim is to use this knowledge to open new pathways towards a cure for myeloma.

Outputs

https://www.amrc.org.uk/blog/partnering-for-progress-amrc-members-and-sgc-oxford

Close-up photograph of a hand holding a mobile phone.

Stay in touch

We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.